Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Navigators Prove Crucial in Improving Genomic Testing Rates Among Black Patients With Prostate Cancer

      October 13, 2023
      By Lindsay Fischer
      News
      Article
      Conferences|American Society for Therapeutic Radiology and Oncology (ASTRO)

      Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.

      Alexander J. Allen, MD

      Alexander J. Allen, MD

      The percentage of Black patients with prostate cancer who were referred to genomic testing greatly increased following the introduction of a precision medicine navigator, according to a presentation from the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.

      The job for one of these clinical navigators is to focus exclusively on identifying candidates for genomic testing and ensuring that the tests are completed. After identifying patients who would benefit from testing, these navigators help the patients fill out requisition forms and coordinate the submission of biopsied tissue to the testing company.

      Investigators are optimistic that precision medicine navigators can help this patient population better predict high-risk disease and increase their likelihood of receiving appropriate treatment.

      “Our findings suggest hiring a precision medicine navigator who specializes in genetic testing can improve the rates of Black patients receiving these tests, which could potentially reduce health disparities and improve outcomes,” Alexander J. Allen, MD, a radiation oncology resident physician at the University of Maryland Medical Center in Baltimore, stated in a press release, noting that for many patients, treatment was adjusted to consider the findings of the genomic tests.

      “The most common way treatments were altered based on genomic testing results was in whether or not patients with intermediate risk disease were given hormone blocking therapy,” he recalled.

      Key Findings

      Investigators compared the rates of testing from 7 months prior and 7 months following the introduction of a precision medicine navigator. Prior to the navigator’s arrival, the referral rate of Black patients for genomic testing was 19%. Following the navigator’s arrival, this number rose to 58%, meaning that Black patients were 6 times more likely to undergo testing with the presence of a navigator.

      Of note, substantial increases in referral were observed for lower-income patients (19% to 58%), those on Medicare and Medicaid (20% to 64%), and those being treated in the community setting (6% to 77%), following the navigator’s arrival.

      The study included a total of 693 patients, 44.9% of whom (n = 311) received treatment prior to the navigator arrival and 55.1% (n = 382) of whom were treated in a postnavigator setting. The median patient age was 68 years in both groups, and the breakdown of races was similar between the 2 groups as well, with 60% White, 34% Black, 3.2%/3.7% Asian/Pacific Islander patients, and 2.1% Hispanic patients.

      Significance

      Despite being 76% more likely than White patients to be diagnosed with prostate cancer, Black patients with prostate cancer face significant disadvantages within the health care system. Many factors lead to the racial disparity—including a lower screening rate; Black patients with prostate cancer are more likely to receive a diagnosis once their cancer has already become aggressive. Consequently, they are 120% more likely than White patients to die from their prostate cancer.

      Clinicians leverage genomic testing to assess the likelihood that an individual’s cancer will metastasize, often using a test known as Decipher, which assesses RNA markers in samples of the patient’s tumor tissue. At the 2021 ASTRO Meeting, research presented suggested that genomic tests may be better predictors of high-risk disease than the conventional method of assessing Gleason score and prostate-specific antigen levels. However, Allen said that oncologists today use all 3 tests to guide treatment decisions.

      “Genomic testing provides additional information that can alter a patient’s treatment plan,” he said. “For example, if Gleason scores and PSA levels suggest a patient has an intermediate risk for metastases, but the genetic analysis categorizes them at high risk because of the biological makeup of the tumor, then you might intensify treatment.”

      Allen’s team is currently working on a study which will assess whether the increased rate of genomic testing results in better treatment outcomes—operating on the assumption that better risk stratification will lead to better treatment results.

      The Caveat

      Because traditional business models do not financially support precision medicine navigators, novel funding mechanisms may be necessary to increase their availability and decreased disparities.

      Moreover, ensuring that these services are available to all patients who might benefit will remain a crucial part of lessening disparities in prostate cancer moving forward.

      “As precision medicine becomes more mainstream, it has the potential to alleviate disparities,” Allen concluded. “But if there are no measures taken to ensure access to these tools, we could just be maintaining or even worsening the health inequities that we have today.”

      References

      1. Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer.News release. ASTRO. October 1, 2023. Accessed October 10, 2023. https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2023/Precision-medicine-navigators-increase-genomic-tes
      2. Allen AJ, Savla B, Datnow-Martinez C, et al. The impact of a precision medicine navigator on inequities associated with utilization of genomic tests in Black men with prostate cancer. Presented at: 2023 American Society for Radiation Oncology Annual Meeting (ASTRO); September 30 to October 4, 2023; San Diego, CA. Abstract 122.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Image of a woman with a blue background
      Image of a man in scrubs with short hair and glasses
      Image of a woman with dark hair wearing a floral shirt in front of a blurred background
      Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
      Related Content

      Image of a pediatric patient with a headwrap with an upset face holding a teddy bear

      Racial, Ethnic Disparities Present in Pediatric Brain Cancer Survival

      Russ Conroy
      May 8th 2025
      Article

      Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.


      The Vitals

      Racism Is Still Prevalent in Nursing

      Patricia Jakel, MN, RN, AOCN
      October 17th 2023
      Podcast

      Quanna Batiste-Brown, DNP, RN, NEA-BC, FAAN, and Patricia Jakel, RN, MN, AOCN, discuss the reality of racism in nursing.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      The Vitals

      Linda Bloom Shares Strategies To Improve Presurgical Communication With Patients Who Have Limited English Proficiency

      Lindsay Fischer
      August 14th 2023
      Podcast

      Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.


      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.

      Related Content

      Image of a pediatric patient with a headwrap with an upset face holding a teddy bear

      Racial, Ethnic Disparities Present in Pediatric Brain Cancer Survival

      Russ Conroy
      May 8th 2025
      Article

      Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.


      The Vitals

      Racism Is Still Prevalent in Nursing

      Patricia Jakel, MN, RN, AOCN
      October 17th 2023
      Podcast

      Quanna Batiste-Brown, DNP, RN, NEA-BC, FAAN, and Patricia Jakel, RN, MN, AOCN, discuss the reality of racism in nursing.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      The Vitals

      Linda Bloom Shares Strategies To Improve Presurgical Communication With Patients Who Have Limited English Proficiency

      Lindsay Fischer
      August 14th 2023
      Podcast

      Linda Bloom, MPA, RN, OCN, highlights how tools such as audio interpretation technology and clear masks can help nurses and patients overcome communication barriers in oncology.


      Line illustration of red blood cells on a yellow background

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      Russ Conroy
      April 20th 2025
      Article

      Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.


      Image of red blood cells

      Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

      Jax DiEugenio
      April 19th 2025
      Article

      Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.

      Latest Conference Coverage

      Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.